Skip to Content

Kindred Biosciences, Inc. 

Merger

  • Date:
  • 6/16/2021
  • Company Name:
  • Kindred Biosciences, Inc.
  • Stock Symbol:
  • KIN
  • Company Name - Buyer:
  • Elanco Animal Health Incorporated
  • Stock Symbol - Buyer:
  • ELAN
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 6/16/2021

Case Finder

Locate any case using the tools below.

NEW YORK, June 16, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Kindred Biosciences, Inc. (NASDAQ: KIN) (“KindredBio”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Elanco Animal Health Incorporated (NYSE: ELAN).

On June 16, 2021, KindredBio announced that it had signed an agreement to merge with Elanco for approximately $440 million.  Pursuant to the merger agreement, KindredBio stockholders will receive $9.25 in cash for each share of KindredBio common stock owned.  The deal is scheduled to close in the third quarter of 2021.

Bragar Eagel & Squire is concerned that KindredBio’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for KindredBio’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Kindred Biosciences. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: